General Information of Drug (ID: DMRT69H)

Drug Name
PNU-177864 Drug Info
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Terminated [1]
Cross-matching ID
PubChem CID
56972219
TTD Drug ID
DMRT69H

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Dopamine D3 receptor (D3R)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cariprazine DMJYDVK Bipolar disorder 6A60 Approved [2]
Pramipexole DMNMW9R Parkinson disease 8A00.0 Approved [3]
Ropinirole DMA6S1D Parkinson disease 8A00.0 Approved [3]
CM-2395 DMASPWR Schizophrenia 6A20 Phase 3 [4]
P2B-001 DM9PVHX Parkinson disease 8A00.0 Phase 3 [5]
RP5063 DMKUE8O Schizophrenia 6A20 Phase 2 [6]
ONC201 DMM5SCF Endometrial cancer 2C76 Phase 2 [7]
TAK-906 DMBQD9H Diabetic gastroparesis DA41.00 Phase 2 [8]
GSK598809 DMGU05N Drug abuse 6C4G.1Z Phase 2 [9]
GSK618334 DMJPXZ4 Drug abuse 6C4G.1Z Phase 1 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D3 receptor (D3R) TT4C8EA DRD3_HUMAN Antagonist [1]

References

1 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
2 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
5 Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease. Clin Neuropharmacol. 1998 May-Jun;21(3):141-51.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK-906), a Novel Selective D 2 /D 3 Receptor Antagonist: A Phase 1 Randomized, Placebo-Controlled Single- and Multiple-Dose Escalation Study in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Jan 18.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).